NEWS AND MEDIAS

  • 16.04.2020
  • Neurology

Interview

The neurological impact of COVID-19: Interview of Pr. Vespignani

  • 24.01.2020
  • france
  • Global

Syndicate Loan

BNP Paris and CA Champagne Bourgogne sign a syndicate loan with Bioserenity.

  • 21.01.2020
  • france
  • Global

"Made in France" exhibition

"Made in France" exhibition, BioSerenity at the Elysée Palace

  • 16.04.2020
  • Neurology

Interview

The neurological impact of COVID-19: Interview of Pr. Vespignani

  • 24.01.2020
  • france
  • Global

Syndicate Loan

BNP Paris and CA Champagne Bourgogne sign a syndicate loan with Bioserenity.

  • 21.01.2020
  • france
  • Global

"Made in France" exhibition

"Made in France" exhibition, BioSerenity at the Elysée Palace

our news
  • BY :
  • 16/04/2020
  • Neurology
  • article

The neurological impact of COVID-19: Interview of Pr. Vespignani

19th of April, professor Hervé Vespignani, BioSerenity’s French medical director was interviewed on French live television and radio to talk about neurological consequences observed in COVID-19 patients. In the interview, the professor speaks about the recent discovery made by Neurophy’s team of EEG irregularities in some COVID-19 patients.

These abnormalities, which are characteristics of an encephalitis, show the virus’ impact the cerebral cortex through an inflammatory mechanism. The professor on the behalf of his team, warns the medical population, through these interviews and a coming publication, to stay alert for potential neurological manifestations in COVID-19 patients. He even recommends the systematization of EEG exploration for patients in reanimation that experienced a delay in waking-up from the induced coma, for the more severe patients that required respiratory support.

Indeed, this delay, if not explained by complications linked to the sedation could be explained by the inflammation. Hence the importance of performing an EEG as soon as possible to avoid any neurological consequences due to the delay in diagnosing the encephalitis.

  • 24/01/2020
  • france
  • Global
  • article

BNP Paris and CA Champagne Bourgogne sign a syndicate loan with Bioserenity.

East of France, January 16th, 2020 – In only 6 year, BioSerenity has becomed one of the world leaders in electrophysiology. The company is currently experiencing a strong growth and was able to impose its leadership is France and in the US, through its range of expertise in electroencephalogram (EEG), electrocardiogram (ECG), and in sleep disorders. Thanks to the financial support of BNP Paribas and Crédit Agricole Champagne Bourgogne, the company will continue USA and European markets exploration.
  • 21/01/2020
  • france
  • Global
  • article

"Made in France" exhibition, BioSerenity at the Elysée Palace

Paris, January 18th, 2020 – BioSerenity exhibited a prototype of a connected textile, suitable for a pediatric use, at the “Made in France” exhibition, held at the Elysée Palace in Paris this weekend.

BioSerenity’s medical devices are developed and manufactured in France, in Rosières-prés-Troyes factory, capitalizing on a territorial know-how in textile. At the crossroads of digital and medical innovation, BioSerenity offers connected medical devices, providing continuous and long-term recording at the patient’s home or at the hospital, to help healthcare professionals to diagnose and support their patients.

  • 11/12/2019
  • france
  • Psychiatry
  • article

BioSerenity attended the French Congress of Psychiatry

Nice, december 4th 2019 – BioSerenity and its medical subsidiary company attended the French Congress of Psychiatry in Nice, between the 4th and 7th december 2019. 

During this event, the interest of alectrophysiology in psychiatry was highlighted during a workshop moderated by Prof. Schwan (Nancy) in presense of Dr. Micoulaud-Franchi (Bordeaux), Pr. Vespignani (Nancy ) and Dr. Schwitzer (Nancy). In particular, during this conference, the importance of electrophysiological monitoring (EEG, PSG and ERG) in psychiatry was emphasized.

More particularly, according to the speakers, the evaluation of the EEG as part of the patient journey in psychiatry should be used as a bioelectric marker of pathologies treatable by non-psychiatric therapeutics, but also as a bioelectric marker of the response and tolerance to treatments, particularly in narrow margin specialized therapies. In addition, EEG could be used as a bioelectric marker in a psychophysiological perspective to consider personalized neuro-modulatory therapies.

Also, psychiatric comorbidities and sleep have been highlighted as well as the importance of investigating the patients’ sleep quality in a systematic way in the care pathways in psychiatry.

Finally, the ERG was recognized by stakeholders as a tool for evaluation and prediction of the response to psychiatric treatment and its use could be relevent in clinical practice for the differential diagnosis between unipolar depression and bipolar depression.

  • 27/11/2019
  • france
  • cardiology
  • article

JAFA 2019

Paris, November 22nd – The 12th of December 2019 will be held the Day of Action on Atrial Fibrillation. The Atrial Fibrillation is characterized by an irregular heart rate among other characteristics.

BioSerenity supports this testing and awareness day organized by Action Coeur. Coordinated by the professor Gilles Montalescot, cardiologist within the Cardiolgy Institute of La Pitié Salpêtrière hospital, Action Cœur is an independent academic not for profit Academic Research Organization, acting and promoting clinical research and prevention in the field of cardiovascular diseases.

Join Action Coeur on the 12th of December from 9:00 am to 5:00 pm at the Cardiolgy Institute of La Pitié Salpêtrière hospital to be informed on atrial fibrillation.

 

 

Venez vous informer à l’Institut de Cardiologie à l’Hôpital de la Pitié Salpêtrière le 12 décembre 2019 entre 9h et 17h.

  • 27/11/2019
  • france
  • AI
  • article

Symposium: Health data and collective intelligence

Paris, November 18th – Over the last few years, the AI has invited itself within our everyday lives to improve them. Continuing this trend, the result will may be the change of the health system as we know it today.

In this environment, the BioSerenity team attended to the “Health Data and Collective Intelligence” conference during which the future use of the health data was introduced by the State representatives and health players.

  • 19/11/2019
  • france
  • Global
  • Press release

A new branch of BioSerenity in Nancy University Hospital

Nancy, November 20th, the Nancy-Barbois Regional University Hospital Center opens an economic research project center focused on healthcare, within the Health Research and Innovation Institute.

In this space dedicated to hosting startups, companies under a research agreement with the Regional University Hospital Center, and reaseachers developing innovations, BioSerenity is proud to be part of the first startups opening a new branch in the Technopôle Henri-Poincaré.

For more information please consult our press release. 

  • 23/09/2019
  • france
  • Global
  • Press release

BioSerenity acquires SleepMed

Paris, September 22nd, 2019 – Following its recent integration among the Next40 index, BioSerenity announces the acquisition of SleepMed Inc. a US based provider of Sleep and Neuroscience Diagnostics.

SleepMed operates over 70 Sleep Labs in the continental United States. Through its services, SleepMed has helped diagnose hundreds of thousands of patients suffering from sleep and seizure disorders.

Another significant step which consolidate BioSerenity presence in the USA to become one of the leaders of Sleep Medicine and Neuroscience in the United States.

  • 19/06/2019
  • france
  • Neurology
  • article

Serenity Medical Services at the Clinical Neurophysiology Days

Nancy, June 19th 2019 – Serenity Medical Services, committed to bringing practical solutions to specialists in neurology and sleep disorders, attended the Clinical Neurophysiology 4th Days.

Available 24/7, Neurophy teams are composed by EEG technicians and medical interpreters, neurologists, specialized in EEG from premature infants to adults.

Our CEREVES sleep centers welcome patients from sunday to saturday for a complete care of their sleep disorders, on prescription.

 

  • 18/06/2019
  • france
  • Global
  • Press release

BioSerenity raises €65 million

Paris, June 18th 2019 – BioSerenity, a high growth French startup company that specializes in remote diagnostic technologies and has demonstrated expertise in digital health assessment and management, has raised €65 million (approx.$73) in a Series B funding round, including €50 million in equity financing led by Dassault Systèmes and BioSerenity’s existing investors Idinvest Partners, LBO France, and the PSIM fund, managed by Bpifrance. This fundraising will allow BioSerenity to extend its commercial activities internationally as well as broaden its Internet of Things (IoT) and Artificial Intelligence (AI) health care solutions.

no article available
More More

CONNECTING PATIENTS WITH THEIR HEALTHCARE PROVIDERS ANYTIME AND ANYWHERE

One of the leading global providers of remote diagnostic solutions

HEALTHCARE SERVICES RESEARCH & CLINICAL TRIALS

BioSerenity, through its telemedicine subsidiaries, is currently deploying technologists and physicians to perform and interpret electrophysiological evaluations, and to remotely monitor patients.